Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Vet Res ; 54(1): 82, 2023 Sep 27.
Artículo en Inglés | MEDLINE | ID: mdl-37759311

RESUMEN

Immune checkpoint molecules PD-1/PD-L1 cause T-cell exhaustion and contribute to disease progression in chronic infections of cattle. We established monoclonal antibodies (mAbs) that specifically inhibit the binding of bovine PD-1/PD-L1; however, conventional anti-PD-1 mAbs are not suitable as therapeutic agents because of their low binding affinity to antigen. In addition, their sensitivity for the detection of bovine PD-1 is low and their use for immunostaining PD-1 is limited. To address these issues, we established two anti-bovine PD-1 rabbit mAbs (1F10F1 and 4F5F2) and its chimeric form using bovine IgG1 (Boch1D10F1), which exhibit high binding affinity. One of the rabbit mAb 1D10F1 binds more strongly to bovine PD-1 compared with a conventional anti-PD-1 mAb (5D2) and exhibits marked inhibitory activity on the PD-1/PD-L1 interaction. In addition, PD-1 expression in bovine T cells could be detected with higher sensitivity by flow cytometry using 1D10F1. Furthermore, we established higher-producing cells of Boch1D10F1 and succeeded in the mass production of Boch1D10F1. Boch1D10F1 exhibited a similar binding affinity to bovine PD-1 and the inhibitory activity on PD-1/PD-L1 binding compared with 1D10F1. The immune activation by Boch1D10F1 was also confirmed by the enhancement of IFN-γ production. Finally, Boch1D10F1 was administered to bovine leukemia virus-infected cows to determine its antiviral effect. In conclusion, the high-affinity anti-PD-1 antibody developed in this study represents a powerful tool for detecting and inhibiting bovine PD-1 and is a candidate for PD-1-targeted immunotherapy in cattle.


Asunto(s)
Antígeno B7-H1 , Interferón gamma , Femenino , Bovinos , Conejos , Animales , Receptor de Muerte Celular Programada 1/metabolismo , Antivirales , Anticuerpos Monoclonales
2.
Vet Microbiol ; 254: 108976, 2021 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-33453627

RESUMEN

Diarrhea is a major cause of death in calves and this is linked directly to economic loss in the cattle industry. Fermented milk replacer (FMR) has been used widely in clinical settings for calf feeding to improve its health and growth. However, the protective efficacy of FMR on calf diarrhea remains unclear. In this study, we verified the preventive effects of FMR feeding on calf diarrhea using an experimental infection model of bovine rotavirus (BRV) in newborn calves and a field study in dairy farms with calf diarrhea. In addition, we evaluated the protective efficacy of lactic acid bacteria-supplemented milk replacer (LAB-MR) in an experimental infection model. In the experimental infection, calves fed FMR or high-concentrated LAB-MR had diarrhea, but the water content of feces was lower and more stable than that of calves fed normal milk replacer. The amount of milk intake also decreased temporarily, but recovered immediately in the FMR- and LAB-MR-fed calves. As compared with the control calves, FMR- or LAB-MR-fed calves showed less severe or reduced histopathological lesions of enteritis in the intestinal mucosa. In a field study using dairy calves, FMR feeding significantly reduced the incidence of enteritis, mortality from enteritis, duration of a series of treatment for enteritis, number of consultations, and cost of medical care for the disease. These results suggest that feeding milk replacer-based probiotics to calves reduces the severity of diarrhea and tissue damage to the intestinal tract caused by BRV infection and provides significant clinical benefits to the prevention and treatment of calf diarrhea.


Asunto(s)
Alimentación Animal/análisis , Diarrea/prevención & control , Diarrea/veterinaria , Enteritis/veterinaria , Leche , Probióticos/administración & dosificación , Infecciones por Rotavirus/prevención & control , Infecciones por Rotavirus/veterinaria , Animales , Bovinos , Enfermedades de los Bovinos/prevención & control , Enfermedades de los Bovinos/virología , Productos Lácteos Cultivados , Diarrea/terapia , Suplementos Dietéticos , Enteritis/prevención & control , Femenino , Mucosa Intestinal/patología , Mucosa Intestinal/virología , Masculino , Embarazo , Probióticos/uso terapéutico , Infecciones por Rotavirus/terapia , Destete
3.
J Immunol ; 203(5): 1313-1324, 2019 09 01.
Artículo en Inglés | MEDLINE | ID: mdl-31366713

RESUMEN

Bovine leukemia virus (BLV) infection is a chronic viral infection of cattle and endemic in many countries, including Japan. Our previous study demonstrated that PGE2, a product of cyclooxygenase (COX) 2, suppresses Th1 responses in cattle and contributes to the progression of Johne disease, a chronic bacterial infection in cattle. However, little information is available on the association of PGE2 with chronic viral infection. Thus, we analyzed the changes in plasma PGE2 concentration during BLV infection and its effects on proviral load, viral gene transcription, Th1 responses, and disease progression. Both COX2 expression by PBMCs and plasma PGE2 concentration were higher in the infected cattle compared with uninfected cattle, and plasma PGE2 concentration was positively correlated with the proviral load. BLV Ag exposure also directly enhanced PGE2 production by PBMCs. Transcription of BLV genes was activated via PGE2 receptors EP2 and EP4, further suggesting that PGE2 contributes to disease progression. In contrast, inhibition of PGE2 production using a COX-2 inhibitor activated BLV-specific Th1 responses in vitro, as evidenced by enhanced T cell proliferation and Th1 cytokine production, and reduced BLV proviral load in vivo. Combined treatment with the COX-2 inhibitor meloxicam and anti-programmed death-ligand 1 Ab significantly reduced the BLV proviral load, suggesting a potential as a novel control method against BLV infection. Further studies using a larger number of animals are required to support the efficacy of this treatment for clinical application.


Asunto(s)
Anticuerpos/farmacología , Antígeno B7-H1/inmunología , Inhibidores de la Ciclooxigenasa 2/farmacología , Dinoprostona/farmacología , Leucosis Bovina Enzoótica/tratamiento farmacológico , Inmunidad/efectos de los fármacos , Virus de la Leucemia Bovina/efectos de los fármacos , Animales , Antivirales/farmacología , Bovinos , Ciclooxigenasa 2/metabolismo , Leucosis Bovina Enzoótica/inmunología , Leucosis Bovina Enzoótica/virología , Virus de la Leucemia Bovina/inmunología , Provirus/efectos de los fármacos , Provirus/inmunología , Carga Viral/efectos de los fármacos , Carga Viral/inmunología
4.
J Vet Med Sci ; 68(2): 175-8, 2006 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-16520542

RESUMEN

In this study, we investigated whether ozonated autohemoadministration (OAHA) influences leukocyte populations in cows with clinical inflammatory disease. Eleven cows with inflammatory disease (Inflammatory Group) and three healthy cows (Control Group) were used for this study. The CD4(+)/CD8(+) ratio in the Inflammatory Group increased significantly compared to that in the Control Group 3 to 4 days after OAHA treatment. In the Inflammatory Group, the number of CD14(+) cells decreased gradually after OAHA, but CD14(+) levels remained stable in the Control Group. The number of MHC class-II(+) cells decreased gradually in the Inflammatory Group, but increased gradually in the Control Group, and the difference between the groups was significant on day 14 after OAHA. These findings suggest a possible difference in the activation of immune response after OAHA in infected cows compared to healthy cows.


Asunto(s)
Artritis/inmunología , Enfermedades de los Bovinos/inmunología , Úlcera del Pie/inmunología , Mastitis Bovina/inmunología , Ozono/uso terapéutico , Linfocitos T/efectos de los fármacos , Linfocitos T/inmunología , Animales , Artritis/tratamiento farmacológico , Relación CD4-CD8/veterinaria , Linfocitos T CD4-Positivos/inmunología , Linfocitos T CD8-positivos/inmunología , Bovinos , Enfermedades de los Bovinos/tratamiento farmacológico , Femenino , Úlcera del Pie/tratamiento farmacológico , Inflamación/tratamiento farmacológico , Inflamación/inmunología , Receptores de Lipopolisacáridos/inmunología , Recuento de Linfocitos/veterinaria , Mastitis Bovina/tratamiento farmacológico
5.
J Vet Med Sci ; 64(8): 723-6, 2002 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-12237520

RESUMEN

The effects of chlorpromazine (CPZ), pentoxifylline (PTX) and dexamethasone (DEX) on mRNA expression of lipopolysaccharide (LPS)-induced proinflammatory cytokines were examined in bovine peripheral blood mononuclear cells (PBMCs) in vitro. The expression of inflammatory cytokine mRNAs was analyzed by RT-PCR and Southern blot hybridization in bovine PBMCs. CPZ and DEX decreased the expression of cytokine mRNA (such as interleukin-1 beta and tumor necrosis factor-alpha) after stimulation with LPS in a dose-dependent manner. However, pretreatment with PTX had no inhibitory effect on the mRNA expression of proinflammatory cytokines. These results indicated that pretreatment with CPZ and DEX might be effective to reduce the production of LPS-induced inflammatory cytokines in bovine PBMCs in vitro.


Asunto(s)
Clorpromazina/farmacología , Citocinas/biosíntesis , Dexametasona/farmacología , Leucocitos Mononucleares/efectos de los fármacos , Pentoxifilina/farmacología , ARN Mensajero/metabolismo , Animales , Antiinflamatorios/farmacología , Southern Blotting , Bovinos , Citocinas/genética , Relación Dosis-Respuesta Inmunológica , Regulación de la Expresión Génica , Leucocitos Mononucleares/inmunología , Lipopolisacáridos/farmacología , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...